|21st October 2020||Michael Aaron Kelly||5,754||Grant/award etc.||$0.00|
|30th September 2020||Bruce K Crowther||1,036||Grant/award etc.||$43.62||$45,190.32|
|29th September 2020||Steven C Jones||81,000||Open or private sale||$36.55||$2,960,550.00|
|29th September 2020||Steven C Jones||141,049||Open or private sale||$36.95||$5,211,760.55|
|29th September 2020||Steven C Jones||25,000||Bona fide gift||$0.00|
|28th September 2020||Steven C Jones||38,951||Open or private sale||$36.34||$1,415,479.34|
|28th September 2020||Steven C Jones||19,000||Open or private sale||$36.56||$694,640.00|
|24th September 2020||Bruce K Crowther||8,333||Exercise of derivative||$9.11||$75,913.63|
|24th September 2020||Bruce K Crowther||8,333||Open or private sale||$35.01||$291,738.33|
|22nd September 2020||Bruce K Crowther||2,400||Open or private sale||$35.68||$85,632.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
NeoGenomics, Inc. specializes in cancer genetics diagnostic testing and pharma services. It operates through two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.